Archive | NAIT RSS for this section

New Agent and Innovative Therapies Program (NAIT) October newsletter available now

Download the newsletter here: https://gallery.mailchimp.com/0a22c0fb4750c9511cde46055/files/b29d02a7-b710-4dba-a1d4-e07a75d3d609/NAIT_newsletter_October_2019.pdf

UPDATES
  • ADVL1412 (nivolumab/ipilimumab) has now reopened for patients with Ewing sarcoma and rhabdomyosarcoma. Patients should have available archival tissue but are not required to demonstrate PDL1 expression for enrolment.
  • Venetoclax study has now reopen at SickKids for patients with solid tumours
  • ymAbs201 (hu3F8) – we have treated the first patient in Canada on this protocol – for consolidation of response in primary or secondary refractory/residual disease in HR neuroblastoma

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) September newsletter available now

UPDATES:

  • ADVL1412 (nivolumab/ipilimumab) is being amended to reopen for patients with Ewing sarcoma and rhabdomyosarcoma. Patients should have available archival tissue but are not required to demonstrate PDL1 expression for enrollment.

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) August newsletter available now

UPDATES:

  • ADVL1412 (nivolumab/ipilimumab) is being amended to reopen for patients with Ewing sarcoma and rhabdomyosarcoma. Awaiting REB approval.
  • Tazemetostat Phase I study – Cohort for patients with ATRT is now closed

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

New Agent and Innovative Therapies Program (NAIT) Newsletter Early phase trials at SickKids

Studies for which funding is likely to be available from the trial itself are indicated in the table in the newsletter. For more information, please email: nait.info@sickkids.ca

Additional contacts:
  • Solid tumour: Dr Daniel Morgenstern daniel.morgenstern@sickkids.ca
  • CNS: Dr Eric Bouffet eric.bouffet@sickkids.ca
  • Leukaemia/lymphoma: Dr Jim Whitlock jim.whitlock@sickkids.ca
  • Patient Navigator: Karen Fung karen.fung@sickkids.ca

Please note that study status can change frequently and information above may become out of date. Please contact us to discuss currently availability for potential patients.

Helping families navigate:

To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health. Please contact us for more information.

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

Now open at Sick Kids: NANT 2015-02 Phase I study of LORLATINIB and LOXO-TRK-15003 Phase I/II study of LAROTRECTINIB

NANT 2015-02 Phase I study of LORLATINIB (ALK inhibitor)

  • Relapsed/refractory neuroblastoma only
  • Need confirmed ALK activating mutation or ALK amplification*
  • Need evaluable or measurable disease
  • Oral medication
  • Academic study, therefore no funding for patient travel/accommodation

* ALK testing is not available as part of the study, but please contact us since we have the assay available at SickKids


LOXO-TRK-15003 Phase I/II study of LAROTRECTINIB (LOXO-101, NTRK inhibitor)

  • Relapsed/refractory solid tumour or CNS tumour, particularly relevant for infantile fibrosarcoma
  • Need a documented NTRK fusion
  • Need evaluable or measurable disease
  • Oral medication
  • Pharma company funding is available to assist with patient travel/accommodation

NAIT August Newsletter Available Now – CTL019 now open

CTL019 CAR-T study now open at Sick Kids: Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients   see: https://clinicaltrials.gov/ct2/show/NCT02228096

The August 2017 NAIT newsletter can be found HERE.

For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

NEW AGENTS & INNOVATIVE THERAPY PROGRAM – July newsletter available

TACL 2014-001 now open at Sick Kids (also open at Ste-Justine and BC Children’s):  A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma.  For more information see: https://clinicaltrials.gov/ct2/show/NCT01614197

 

The July 2017 NAIT newsletter can be found HERE..

For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

NEW AGENTS & INNOVATIVE THERAPY PROGRAM – June newsletter available

The NAIT June newsletter is available here: NAIT Newletter June 2017
The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and SickKids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical

NAIT: KTE-C19 CAR T cell study open + May newsletter available

KTE-C19 now open: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia.  For more information see:  https://clinicaltrials.gov/ct2/show/NCT02625480

 

The May 2017 NAIT newsletter can be found HERE.  For more information on current and upcoming trials, please visit www.sickkids.ca/centres/gfcc/nait/index.html or send an email directly to nait.info@sickkids.ca

Solid Tumours: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.

April NAIT newsletter available now

The April 2017 NAIT newsletter can be found HERE.

For more information on current and upcoming trials, please visit

www.sickkids.ca/centres/gfcc/nait/index.html

or send an email directly to nait.info@sickkids.ca

Solid Tumour: Dr. Daniel Morgenstern
Leukemia/Lymphoma: Dr. Jim Whitlock
CNS: Dr. Eric Bouffet
Patient Navigator: Karen Fung

BOOKMARK NAIT:  The current list of all open trials can be found on the NAIT Website at http://www.sickkids.ca/HaematologyOncology/nait/trials/index.html

HELPING FAMILIES NAVIGATE:  To assist patients and families with their transition, our Patient Navigator Program will collaborate with your team and the family to provide assistance with issues related to travel, accommodation, and navigating their way around the hospital and in the city. Furthermore, for patients living outside of Ontario, our Patient Navigator will assist physicians in completing an Out-of-Province Prior Approval Application to the Provincial Ministry of Health.

The vision of the New Agents and Innovative Therapy Program (NAIT) supports The Garron Cancer Centre and Sick Kids’ commitment to innovation and providing Canadian children and their families living with cancer with greater access to the best and newest treatment that will assist to improve clinical care.